HIV patients benefit from dual drug treatmentBMJ 2001; 323 doi: http://dx.doi.org/10.1136/bmj.323.7309.360/b (Published 18 August 2001) Cite this as: BMJ 2001;323:360
- Scott Gottlieb
- New York
Some patients with HIV infection are more likely to benefit from treatment using a combination of two enzyme inhibitors than with either of the drugs on its own, a new study has reported.
For patients who have failed nucleoside analogue therapy, the protease inhibitor nelfinavir combined with the non-nucleoside reverse transcriptase inhibitor efavirenz is more effective than either of the drugs alone, said a report from Dr Mary Albrecht …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial